In light of research has predominantly indicated that CXCL9 is linked to the response to ICI in advanced cancer patients, the observed increase in CXCL9 expression in older individuals, as a response marker for emerging immune-oncology treatments in this population (28, 58, 169). Here, CXCL9 is linked to cancer.